The BDNF/NT 3 Growth Factors Receptor pipeline drugs market research report outlays comprehensive information on the BDNF/NT 3 Growth Factors Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the BDNF/NT 3 Growth Factors Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, Cardiovascular, and Genetic Disorders which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Alzheimer’s Disease, Parkinson’s Disease, Acute Ischemic Stroke, Left Ventricular Dysfunction, Spinocerebellar Ataxia (SCA), and Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis). It also reviews key players involved in BDNF/NT 3 Growth Factors Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The BDNF/NT 3 Growth Factors Receptor pipeline targets constitutes close to 46 molecules. Out of which, approximately 41 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 2, 5, 6, 1, 16, and 9 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 1 molecule.
BDNF/NT 3 Growth Factors Receptor overview
BDNF/NT-3 growth factors receptor is a protein encoded by the NTRK2 gene. It is involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. It acts as receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. It alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation.
For a complete picture of BDNF/NT 3 Growth Factors Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
